Justin Arnall, PharmD, FCCP, BCOP / Anthony J. Perissinotti, PharmD, BCOP - Dispensing High-Quality Care for Myelofibrosis: Pharmacist Leadership in Delivering Effective JAKi Therapy

About this episode

The episode discusses the role of pharmacists in delivering effective JAKi therapy for myelofibrosis.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KCA865. CME/CPE/IPCE credit will be available until April 30, 2027. Dispensing High-Quality Care for Myelofibrosis: Pharmacist Leadership in Delivering Effective JAKi Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This educational activity is supported by an independent medical education grant from GSK. Disclosure information is available at the beginning of the video presentation.

People in this episode

Guests: Justin Arnall, PharmD, FCCP, BCOP, Anthony J. Perissinotti, PharmD, BCOP

Topics covered

• Myelofibrosis
• Pharmacist Leadership
• JAKi Therapy
• Patient Care
• Continuing Education

Keywords

• Myelofibrosis
• JAKi Therapy
• Pharmacist Leadership
• CME
• Patient Care
• Healthcare Professionals

Sponsors

GSK

Mentioned in this episode

Organizations: PeerView Institute for Medical Education, Accreditation Council for Continuing Medical Education, Accreditation Council for Pharmacy Education, American Nurses Credentialing Center

More episodes of PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

• Andrew Kuykendall, MD - Ironing Out the Challenges of PV: Spotlight on Targeting the Hepcidin Pathway for Addressing Unmet Needs and Enhancing Patient Outcomes · June 5, 2026 · 32 min
• Brendon M. Stiles, MD - The Immunotherapy Playbook for Resectable NSCLC: Real-World Challenges and Practical Strategies · June 4, 2026 · 1h 6m
• Charise Gleason, MSN, NP-C, AOCNP / Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - “Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy · May 29, 2026 · 60 min
• Ibrahim Aldoss, MD - Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice · May 29, 2026 · 38 min
• Jaume Capdevila, MD, PhD - Propelling Modern Interventions in Neuroendocrine Carcinoma: Multidisciplinary Principles to Effectively Implement Emerging DLL3-Directed BiTE Therapy in Community Settings · May 29, 2026 · 55 min
• Luke Maese, DO, Rachel Rau, MD - ADAPT to Advance in ALL/LBL: Achieving Durable Asparaginase Exposure With Personalized Treatment in Pediatric and AYA Patients · May 29, 2026 · 49 min